Celgene to acquire Pharmion
SUMMIT, New JerseyCelgene Corporation and Pharmion Corporation (Boulder, Colorado) have signed a definitive merger agreement by which Celgene will acquire all of the outstanding shares of Pharmion common stock. The acquisition furthers Celgene's strategy to become a global leader in the hematology/oncology field, the company said in a news release. The transaction brings together three cancer therapies: Celgene's Revlimid (lenalidomide) and Thalomid (thalidomide), and Pharmion's Vidaza (azacitadine).
Elevating the Quality of Cancer Care via Cross-Department Collaboration
Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.